Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.42 |
| ▸ | KCNA4 known ✓ | P22459 | 1/20 | 0.33 |
| ▸ | KCNA1 known ✓ | Q09470 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2634478 | 0.98 | KDM4E (0.44) | KMT2APMP22MEN1BLMKDM4E | |
| SCHEMBL16748713 | 0.89 | GABRG2 (0.41) | KMT2APMP22MEN1BLMKDM4E | |
| Trifluoroacetic Acid SCHEMBL30286292 | 0.88 | CSNK1D (0.43) | KMT2APMP22MEN1BLMKDM4E | |
| SCHEMBL9608994 | 0.86 | KDM4E (0.43) | KMT2AMEN1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1429031 | 0.84 | SCNN1A (0.50) | KMT2APMP22MEN1BLMKDM4E | |
| Hydrochloric Acid SCHEMBL2634029 | 0.80 | HPGD (0.38) | KDM4EALDH1A1HSD17B10L3MBTL1TSHR | |
| SCHEMBL15185777 | 0.80 | KDM4E (0.43) | KMT2AKDM4EALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL18230698 | 0.78 | CA1 (0.42) | KDM4EALDH1A1HSD17B10L3MBTL1LMNA | |
| SCHEMBL12184961 | 0.78 | HPGD (0.38) | KDM4EALDH1A1HSD17B10L3MBTL1TSHR | |
| SCHEMBL12997160 | 0.77 | SMN1; SMN2 (0.41) | KMT2AMEN1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190302026-A1 | Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH | WOOLEY KAREN L (US) | 2019-10-03 | — | — | US | disclosed |
| US-20180335385-A1 | Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH | THE WASHINGTON UNIVERSITY | 2018-11-22 | — | — | US | disclosed |
| US-9662387-B2 | Functional, cross-linked nanostructures for tandem optical imaging and therapy | MALLINCKRODT LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160256550-A1 | FUNCTIONAL, CROSS-LINKED NANOSTRUCTURES FOR TANDEM OPTICAL IMAGING AND THERAPY | MALLINCKRODT LLC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9295650-B2 | Functional, cross-linked nanostructures for tandem optical imaging and therapy | MALLINCKRODT LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150346099-A1 | Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH | WOOLEY KAREN L (US) | 2015-12-03 | — | — | US | disclosed |
| US-20130210156-A1 | Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH | THE TEXAS A&M UNIVERSITY SYSTEM | 2013-08-15 | — | — | US | disclosed |
| US-20130137976-A1 | Functional, Cross-Linked Nanostructures for Tandem Optical Imaging and Therapy | IKARIA THERAPEUTICS LLC | 2013-05-30 | — | — | US | disclosed |
| EP-2571529-A2 | FUNCTIONAL, CROSS-LINKED NANOSTRUCTURES FOR TANDEM OPTICAL IMAGING AND THERAPY | Mallinckrodt LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011143540-A1 | UNIFORM, FUNCTIONALIZED, CROSS-LINKED NANOSTRUCTURES FOR MONITORING pH | MALLINCKRODT LLC (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143524-A2 | FUNCTIONAL, CROSS-LINKED NANOSTRUCTURES FOR TANDEM OPTICAL IMAGING AND THERAPY | MALLINCKRODT LLC (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20100311903-A1 | Photonic Shell-Core Cross Linked and Functionalized Nanostructures for Biological Applications | MALLINCKRODT LLC | 2010-12-09 | — | — | US | disclosed |
| EP-2217281-A2 | PHOTONIC SHELL-CORE CROSS LINKED AND FUNCTIONALIZED NANOSTRUCTURES FOR BIOLOGICAL APPLICATIONS | Mallinckrodt Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061473-A2 | PHOTONIC SHELL-CORE CROSS LINKED AND FUNCTIONALIZED NANOSTRUCTURES FOR BIOLOGICAL APPLICATIONS | MALLINCKRODT INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256550-A1 | FUNCTIONAL, CROSS-LINKED NANOSTRUCTURES FOR TANDEM OPTICAL IMAGING AND THERAPY | MTCL3, EPHA2, UACA | MAOB 1895/4885KCNA4 3413/4885KCNA1 3617/4885 |
| US-20190302026-A1 | Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH | MUC1, CD44, PFN1 | MAOB 3976/4885KCNA4 4203/4885KCNA1 3662/4885 |
| US-20130137976-A1 | Functional, Cross-Linked Nanostructures for Tandem Optical Imaging and Therapy | MTCL3, EPHA2, UACA | MAOB 1895/4885KCNA4 3413/4885KCNA1 3617/4885 |
| US-20180335385-A1 | Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH | MUC1, CD44, PFN1 | MAOB 3976/4885KCNA4 4203/4885KCNA1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.